Multiple Myeloma in Relapse Clinical Trials

22 recruiting

Multiple Myeloma in Relapse Trials at a Glance

22 actively recruiting trials for multiple myeloma in relapse are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 1 with 11 trials, with the heaviest enrollment activity in Kunming, West Hollywood, and Hangzhou. Lead sponsors running multiple myeloma in relapse studies include Oncotherapeutics, Chongqing Precision Biotech Co., Ltd, and Zhejiang University.

Browse multiple myeloma in relapse trials by phase

Treatments under study

About Multiple Myeloma in Relapse Clinical Trials

Looking for clinical trials for Multiple Myeloma in Relapse? There are currently 22 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Multiple Myeloma in Relapse trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Multiple Myeloma in Relapse clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 22 trials

Recruiting
Phase 1

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma in Relapse
Kelonia Therapeutics, Inc.70 enrolled7 locationsNCT07075185
Recruiting
Phase 1

TriPRIL CAR T Cells in Multiple Myeloma

Multiple MyelomaMultiple Myeloma in RelapseRefractory Multiple Myeloma
Marcela V. Maus, M.D.,Ph.D.18 enrolled1 locationNCT05020444
Recruiting
Phase 2

Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse

Multiple Myeloma in Relapse
Larysa Sanchez23 enrolled1 locationNCT06827860
Recruiting
Not Applicable

Universal CAR-T Cell Therapy for MM

Multiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma, Refractory
Bioray Laboratories6 enrolled1 locationNCT07248176
Recruiting
Not Applicable

Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma

Multiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma, Refractory+2 more
University Health Network, Toronto144 enrolled1 locationNCT06485076
Recruiting
Phase 2

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Multiple MyelomaRelapseMultiple Myeloma in Relapse+1 more
Andrew Yee, MD43 enrolled3 locationsNCT04176718
Recruiting
Phase 1

BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma

Multiple Myeloma in RelapseRefractory Multiple MyelomaPlasmacytoid; Lymphoma
iCell Gene Therapeutics12 enrolled2 locationsNCT04162353
Recruiting
Phase 2

HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM

Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Duke University27 enrolled1 locationNCT06822972
Recruiting
Phase 1

A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies

NeoplasmsMultiple Myeloma in RelapseMultiple Myeloma, Refractory+2 more
Technische Universität Dresden16 enrolled1 locationNCT05836896
Recruiting
Phase 1Phase 2

Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma

Multiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma, Refractory+1 more
Essen Biotech60 enrolled1 locationNCT07032129
Recruiting
Phase 1Phase 2

Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory T(11;14) Multiple Myeloma

Multiple MyelomaMultiple Myeloma in Relapse
Universitätsklinikum Hamburg-Eppendorf45 enrolled5 locationsNCT05853965
Recruiting
Phase 1Phase 2

BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

Multiple MyelomaMultiple Myeloma in RelapseNeoplasm, Plasma Cell
Chongqing Precision Biotech Co., Ltd80 enrolled1 locationNCT04271644
Recruiting
Phase 1Phase 2

a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

Multiple MyelomaMultiple Myeloma in RelapseNeoplasm, Plasma Cell
Chongqing Precision Biotech Co., Ltd80 enrolled1 locationNCT04776330
Recruiting

Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma.

Multiple Myeloma in Relapse
University Hospital, Toulouse40 enrolled1 locationNCT06846905
Recruiting
Phase 2

All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma

Multiple Myeloma in RelapseMultiple Myeloma, Refractory
The First Affiliated Hospital of Xiamen University25 enrolled1 locationNCT06158412
Recruiting
Phase 1

A Trial of Selinexor, Ruxolitinib and Methylprednisolone

Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Oncotherapeutics30 enrolled1 locationNCT06225310
Recruiting
Phase 2

A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Oncotherapeutics39 enrolled2 locationsNCT06115135
Recruiting
Phase 1

LMY-920 for Treatment of Relapsed or Refractory Myeloma

Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Luminary Therapeutics30 enrolled1 locationNCT05546723
Recruiting
Phase 1Phase 2

BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma in Relapse
Shenzhen University General Hospital10 enrolled1 locationNCT06644443
Recruiting
Phase 2

Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes

Multiple Myeloma in Relapse
PETHEMA Foundation50 enrolled15 locationsNCT06282978